Imetelstat: Phase II data

Top-line data from 14 patients with ET who were refractory to or intolerant of conventional therapies in an open-label, international Phase II trial showed that imetelstat led to a complete response rate of 93% and a hematologic response rate of 100%. Additionally, 86% of patients with a Janus kinase-2 (JAK-2) mutation achieved a molecular response (n=7). Data were presented at the American Society of Hematology meeting in Atlanta. Based on the results, Geron said the Mayo Clinic began an investigator-sponsored trial of imetelstat in patients with myelofibrosis. Geron also said it is planning a "Phase III-enabling" trial of imetelstat in myelofibrosis. ...